Jefferies analyst Glen Santangelo lowered the firm’s price target on Teladoc to $14 from $16 and keeps a Hold rating on the shares after updating the firm’s model to reflect Q1 results and updated management commentary. The firm is moderating its outlook for the BetterHelp business given year-over-year comps that “continue to trend in the wrong direction,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Levi & Korsinsky LLP Notifies Shareholders of Teladoc Health, Inc.(TDOC) of a Class Action Lawsuit and an Upcoming Deadline
- Teladoc price target lowered to $13.50 from $16.50 at BofA
- Teladoc call volume above normal and directionally bullish
- Teladoc Health Is Providing Free Virtual Health Care Services to Oklahoma Residents Impacted by Tornadoes
- Teladoc price target lowered to $15 from $17 at Wells Fargo